Universität zu Köln

Jachimowicz, Ron D., Borchmann, Sven and Rothe, Achim (2014). Multi-Specific Antibodies for Cancer Immunotherapy. Biodrugs, 28 (4). S. 331 - 344. NORTHCOTE: ADIS INT LTD. ISSN 1179-190X

Full text not available from this repository.

Abstract

Targeted treatment of cancer with monoclonal antibodies has added to the beneficial outcome of patients. In an attempt to improve anti-tumor activity of monoclonal antibodies, multi-specific antibodies have entered the research arena. To date, only a few multi-specific constructs have entered phase III clinical trials, in contrast to classical monoclonal antibodies, which are the standard first-line therapy in several tumor entities. In this review, we will assess selected multi-specific antibodies in pre-clinical and clinical development that may be new treatment options for cancer patients in the very near future. We will further evaluate therapy modalities including the timely distribution or the combination of various therapeutic approaches and assess the potential role of multi-specific antibodies in cancer treatment.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Jachimowicz, Ron D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Sven UNSPECIFIED UNSPECIFIED UNSPECIFIED Rothe, Achim UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-432251
DOI:	10.1007/s40259-014-0091-4
Journal or Publication Title:	Biodrugs
Volume:	28
Number:	4
Page Range:	S. 331 - 344
Date:	2014
Publisher:	ADIS INT LTD
Place of Publication:	NORTHCOTE
ISSN:	1179-190X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MEDULLARY-THYROID CARCINOMA; GROWTH-FACTOR RECEPTOR; TARGETING HUMAN CD19; BISPECIFIC ANTIBODY; TRIFUNCTIONAL ANTIBODY; ANTITUMOR-ACTIVITY; MALIGNANT ASCITES; IMMUNE-SYSTEM; IN-VITRO; PRETARGETED RADIOIMMUNOTHERAPY Multiple languages Oncology; Immunology; Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/43225